FDA Expands the Age Indication for Nerivio® as the First-and-Only REN Wearable for Migraine Treatment for Children Aged Eight and Above

Children aged eight and up now have a prescribed non-drug option to treat migraine early and potentially prevent long-term disability and disease progression, addressing a critical unmet need in pediatric migraine care. BRIDGEWATER, N.J. and NETANYA, Israel, Nov. 14, 2024 /PRNewswire/ –…